Document Detail

Intravenous daclizumab for recalcitrant ocular inflammatory disease.
MedLine Citation:
PMID:  19198869     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To evaluate outcomes of patients with recalcitrant ocular inflammation treated with intravenous daclizumab. METHODS: Retrospective case-series. Seventeen patients (33 eyes) with ocular inflammation who had failed several previous systemic immunomodulatory therapies were included in this study. Daclizumab was infused intravenously at a dose of 1 mg per kilogram every 2 weeks. The dose and intervals were adjusted according to control of inflammation off systemic and/or topical corticosteroid therapy. Control of ocular inflammation without corticosteroid therapy was the primary efficacy end point. RESULTS: The mean patient age at the commencement of daclizumab therapy was 34.8(range 8-64 years). Three patients were less than 16 years of age at the initiation of therapy. The duration of drug use was 23.6 +/- 15.7 months (range 8-68 months), and the time to control inflammation was 9.8 +/- 11.3 weeks, which was achieved in 15 patients (88.2%). Flare-up rate was 44 per 100 person-years follow-up. Fifteen of 33 eyes (45%) had an improvement in the visual acuity, 13 eyes (39.3%) had stable acuities, and five eyes (15%) had a worsening of their acuities. Two patients (14%) exhibited worsening of ocular inflammation, and were declared as treatment failures. Side effects associated with daclizumab included nausea, fatigue and muscle aches. CONCLUSION: Daclizumab is effective in controlling inflammation in patients with stubborn non-infectious ocular inflammation. It has a corticosteroid-sparing effect, can be used as long-term therapy in children and adults, and is capable of inducing durable remission.
Pooja Bhat; Rene A Castañeda-Cervantes; Priyanka P Doctor; C Stephen Foster
Related Documents :
19773289 - Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica.
7803189 - Long-term follow up of patients with common variable immunodeficiency treated with intr...
18566839 - Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intraven...
9195509 - Mortality studies in systemic lupus erythematosus. results from a single center. iii. i...
16138939 - Achieving asthma control.
10910019 - Apheresis and selective adsorption plus immunoglobulin treatment in guillain-barré synd...
15191869 - A new reconstruction method for preventing delayed gastric emptying after pylorus-prese...
18384489 - Stability training of the lumbo-pelvo-hip complex influence stiffness of the hamstrings...
25188599 - How to improve shoulder balance in the surgical correction of double thoracic adolescen...
Publication Detail:
Type:  Journal Article     Date:  2009-02-06
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  247     ISSN:  1435-702X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-02     Completed Date:  2009-06-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  687-92     Citation Subset:  IM    
Massachusetts Eye Research and Surgery Institution, 5 Cambridge Center, 8th Floor, Cambridge, MA 02142, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage,  adverse effects,  therapeutic use*
Follow-Up Studies
Glucocorticoids / administration & dosage
Immunoglobulin G / administration & dosage,  adverse effects,  therapeutic use*
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use*
Infusions, Intravenous
Middle Aged
Retrospective Studies
Treatment Outcome
Uveitis / drug therapy*,  physiopathology
Visual Acuity / physiology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Glucocorticoids; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 152923-56-3/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identification of an ethnic-specific variant (V207M) of the KCNQ1 cardiac potassium channel gene in ...
Next Document:  Role of fructose concentration on cataractogenesis in senile diabetic and non-diabetic patients.